Current studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing significant effects in addressing obesity and related second-type disease. Preclinical information suggest a novel process https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/